Adocia SA (ADOC.PA)
Paris · EUR · Healthcare · Biotechnology
€2.50 (+1.63%) as of
Key statistics
- Market cap
- 50.69M
- Forward P/E
- -0.35
- EPS (TTM)
- -0.7600
- Dividend yield
- 0.00%
- 52-week range
- 2.0100 – 9.7600
- Beta
- 0.39
- Revenue (TTM)
- 2.98M
- Profit margin
- 0.00%
- Analyst target
- €9.45
- Volume
- 57.00k
About Adocia SA
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an ultra rapid insulin; AdOral Sema, an oral form of GLP-1 semaglutide; and AdoXLongSem, a long-lasting injectable formulation of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lyon, France
- Employees
- 80
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.